From the Guidelines
Tresiba doses should be administered every 24 hours, with a starting dose of 10 units once daily and subsequent adjustments based on individual glucose targets, increasing the dose by 1–2 units or 10–15% twice weekly as needed 1. The dosing frequency of Tresiba is based on its unique molecular structure, which provides a flat and stable action profile for more than 24 hours, allowing for flexible dosing times. When initiating Tresiba in insulin-naïve patients with type 2 diabetes, the typical starting dose is 10 units once daily, with subsequent adjustments based on individual glucose targets. For patients switching from other basal insulins, the same unit-to-unit dose can generally be used, though some patients may require dose adjustments. Regular blood glucose monitoring is essential when starting or adjusting Tresiba doses to achieve optimal glycemic control while minimizing the risk of hypoglycemia. Some key points to consider when dosing Tresiba include:
- Starting dose: 10 units once daily
- Dose adjustments: increase by 1–2 units or 10–15% twice weekly as needed
- Monitoring: regular blood glucose monitoring to achieve optimal glycemic control and minimize hypoglycemia risk
- Dosing flexibility: Tresiba can be administered at any time of day, with at least 8 hours between doses, allowing for flexible dosing times.
From the Research
Tresiba Doses
- Tresiba, also known as insulin degludec, is a long-acting basal insulin analogue that can be administered once daily 2.
- The duration of action of Tresiba is over 24 hours, allowing for flexible dosing and reduced risk of hypoglycemia 3, 4.
- Tresiba can be administered at any time of day, with or without food, and can be adjusted to fit individual patient needs 2, 5.
- The flexibility in dosing schedule and reduced risk of nocturnal hypoglycemia make Tresiba a convenient option for patients with type 1 and type 2 diabetes 6, 2.
Administration Frequency
- Tresiba is typically administered once daily, with a consistent dose and timing to maintain optimal glycemic control 2.
- The once-daily dosing frequency of Tresiba can simplify insulin management for patients and physicians, reducing the burden of multiple daily injections 4, 5.
Key Characteristics
- Tresiba has a unique mechanism of action based on multihexamer formation after subcutaneous injection, allowing for a stable and consistent glucose-lowering effect 3.
- The pharmacokinetic and pharmacodynamic profiles of Tresiba are stable, with low within-person variability in absorption and glucose-lowering action 5.